140835-14-9

Usage

Uses

Used in Pharmaceutical Industry:
11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol is used as a pharmaceutical agent for its agonistic effects on the CB1 and CB2 receptors. The compound's interaction with these receptors can potentially be harnessed for therapeutic applications, such as pain management, appetite stimulation, and the treatment of certain neurological disorders.
Used in Research Applications:
In the field of scientific research, 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol serves as a valuable tool for studying the endocannabinoid system and its role in various physiological processes. It can be used to investigate the mechanisms of action of cannabinoids and their potential therapeutic applications.
Used in Drug Development:
Due to its potent agonistic activity at CB1 and CB2 receptors, 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol may be utilized in the development of new drugs targeting these receptors. This could lead to the creation of novel therapeutics for a range of conditions, including chronic pain, inflammation, and neurodegenerative diseases.

Upstream product

• 112924-45-5 dexanabinol 

Relevant academic research and scientific papers

Synthesis and Pharmacological Properties of 11-Hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: A High-Affinity Cannabinoid Agonist

11-Hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol (1) was synthesized from the known cannabimimetic analog (+/-)-nabilone. Racemic 1 was resolved by HPLC on a semipreparative CHIRALCEL OD column (Daicel, Inc.), and pharmacological activities of the individual enantiomers were evaluated in the mouse model. The (-)-enantiomer was found to be much more potent than the (+)-enantiomer in all the four measures with the potency ratios in the production of catalepsy (RI), hypoactivity (SA), hypothermia (RT), and antinociception (TF) being 93, 143, 186, and 322, respectively. The racemic 11α-OH diastereomer (2), a reaction side product, was also evaluated in the mouse model. Only small differences in the pharmacological activity of racemic 1 and 2 were found in the above four measures.

A Novel Probe for the Cannabinoid Receptor

The 1,1-dimethylheptyl (DMH) homologue of 7-hydroxy-Δ6-tetrahydrocannabinol (3) is the most potent cannabimimetic substance reported so far.Hydrogenation of 3 leads to a mixture of the epimers of 5'-(1,1-dimethylheptyl)-7-hydroxyhexahydrocannabinol or to either the equatorial (7) or to the axial epimer (8), depending on the catalysts and conditions used.Compound 7 discriminates for Δ1-THC (2) in pigeons (ED50 = 0.002 mg/kg, after 4.5 h), at the potency level of 3, and binds to the cannabinoid receptor with a KD of 45 pM, considerably lower than the Ki of 180 pM measured for compound 3 and the Ki of 2.0 nM measured for CP-55940 (1), a widely employed ligand.Tritiated 7 was used as a novel probe for the cannabinoid receptor.